Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

hospira uk limited - paklitaxel - 44 - cytostatica

Europäische Union - Slowakisch - EMA (European Medicines Agency)

advanz pharma limited - obeticholic kyseliny - cirhóza pečene, žlčové - liečba žlčou a pečeňou - ocaliva je indikovaný na liečbu primárnej biliárnej cholangitída (tiež známy ako primárna biliárna cirhóza) v kombinácii s kyselinou ursodeoxycholovou sa však (udca) u dospelých pacientov s nedostatočnou odpoveďou na udca alebo ako monoterapia u dospelých neschopných tolerovať udca.

Europäische Union - Slowakisch - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic kyseliny - xanthomatosis, cerebrotendinous; metabolism, inborn errors - liečba žlčou a pečeňou - chenodeoxycholic kyselina je indikovaná pri liečbe vrodených porúch syntézy primárnych žlčových kyselín kvôli nedostatku prolyl sterol 27 (predstavujú ako cerebrotendinózna xantomatóza (ctx)) u dojčiat, detí a dospievajúcich vo veku od 1 mesiaca do 18 rokov a dospelí.

Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

viatris healthcare limited, Írsko - pyridostigmín - 67 - parasympathomimetica

Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - multienzýmy (lipáza, proteáza a ďalšie) - 49 - digestiva, adsorbentia, acida

Slowakei - Slowakisch - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - exemestán - 44 - cytostatica

Europäische Union - Slowakisch - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europäische Union - Slowakisch - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.